Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPRESS trial
2023-509703-33-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jun 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in sepsis and septic shock comparing Empiric meropenem with Empiric piperacillin/tazobactam (2 arms). Primary endpoint: All-cause mortality at day 30. Planned start Jun 2025; status: authorised.
02
Drugs
meropenempiperacillin + tazobactam
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2023-509703-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509703-33-00.